-
Lei Ping meets with deputy head of Russian Federal Service for Surveillance in Healthcare
2026-11-02
On Oct 23, Lei Ping, deputy commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Dmitry Pavlyukov, deputy head of the Federal Service for Surveillance in Healthcare of the Russian Federation (Roszdravnadzor).
-
Traditional medicine regulation and industrial innovation forum held in Beijing
2026-10-27
The Traditional Medicine Regulation and Industrial Innovation Forum, a parallel session of the World Conference on Traditional Medicine 2026, was held in Beijing on Oct 18.
-
Huang Guo meets with African Medicines Agency director-general
2026-10-26
On Oct 17, Huang Guo, commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Delese Mimi Darko, director-general of the African Medicines Agency (AMA), who was in Beijing to attend the World Conference on Traditional Medicine 2026.
-
Huang Guo meets with Hong Kong secretary for health
2026-10-23
On Oct 17, Huang Guo, commissioner of the National Medical Products Administration (NMPA), met with a delegation from the Hong Kong Special Administrative Region (SAR) led by Secretary for Health Lo Chung-mau and Director of Health Dr. Ronald Lam Man-kin in Beijing, who were in the capital to attend the World Conference on Traditional Medicine 2026.
-
Huang Guo meets with heads of drug regulatory authorities of UK, Brazil, Indonesia
2026-09-30
On Sept 19, Huang Guo, commissioner of China's National Medical Products Administration (NMPA), met in Beijing with Lawrence Tallon, chief executive of the UK's Medicines and Healthcare Products Regulatory Agency, Leandro Pinheiro Safatle, director-president of Brazil's National Health Surveillance Agency, Taruna Ikrar, head of Indonesia's Food and Drug Authority (BPOM), and William Adi Teja, deputy I of the BPOM.
-
NMPA signs letter of intent for cooperation with UK’s MHRA
2026-09-30
From Sept 21 to 24, Huang Guo, commissioner of China's National Medical Products Administration (NMPA), led a delegation to the UK for a working visit at the invitation of the British side, in an effort to implement the consensus reached by the leaders of China and the UK and strengthen exchanges and cooperation in pharmaceutical regulation between the two countries.
